Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Gregory Gorgas, CEO of Artelo Biosciences, is scheduled to present on September 13, 2023 at 2:00 PM Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed at https://journey.ct.events/view/a3fb36ce-8e0f-41c1-b530-feebded86361 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.

Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact ARTL@crescendo-ir.com

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com

Staff

Recent Posts

Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed

GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in…

12 hours ago

Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase

This app will connect people with strangers to meditate together in the real world—an invitation…

12 hours ago

IMG Saxony-Anhalt: 2026 in Sight – Saxony-Anhalt Sets the Pace for Future Industries

Despite challenging framework conditions such as high energy prices, the international introduction of tariffs, and…

12 hours ago

Kirby Medical Center Partners with Switchboard, MD to Automate Patient Communication Workflows

ATLANTA, Dec. 19, 2025 /PRNewswire/ -- Switchboard, MD is proud to announce a new enterprise partnership with…

12 hours ago

SIERRA7 RECOGNIZED AS A 2026 ELEV8 GOVCON AWARD WINNER

MCLEAN, Va., Dec. 19, 2025 /PRNewswire/ -- Sierra7, a leader in government healthcare and technology solutions,…

12 hours ago

Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Medome is the first AI technology for Personal Health…

12 hours ago